Ouro Fino Saúde Animal Participações S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 09, 2022
Share
Ouro Fino Saúde Animal Participações S.A. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was BRL 280.72 million compared to BRL 234.84 million a year ago. Net income was BRL 44.8 million compared to BRL 34.77 million a year ago. Basic earnings per share from continuing operations was BRL 0.83312 compared to BRL 0.64456 a year ago. Diluted earnings per share from continuing operations was BRL 0.83312 compared to BRL 0.64456 a year ago.
For the nine months, sales was BRL 718.34 million compared to BRL 634.61 million a year ago. Net income was BRL 84.34 million compared to BRL 76.24 million a year ago. Basic earnings per share from continuing operations was BRL 1.56854 compared to BRL 1.41331 a year ago. Diluted earnings per share from continuing operations was BRL 1.56854 compared to BRL 1.41331 a year ago.
Ouro Fino Saude Animal Participacoes S.A., also known as Ourofino, is a Brazil-based company engaged in the animal health market business sector in Latin America. The Company manufactures veterinary products using scientific technology in the Company's laboratories. The Company's products are divided into six sectors: Wholesale, Birds, Cattle, Equine, Pet and Pigs. The Wholesale area is divided into four lines: Anti-Mastiticos, producing antibiotics killing bacteria and lumps; Antimicrobial, which focuses on the treatment of bacterial infectious diseases; Ectoparasiticides, concentrated on insect repellent products, and Endectocides, which is the treatment and control of internal and external diseases of cattle, sheep and swine parasites. There is also one additional line of products divided for additives, biological, inoculants, diagnostic kit, probiotics, silage and other supplements, among others.
OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A. 
